Kangzhi pharmaceutical industry denies the false increase of profits

Yangcheng Evening News reporter Wu Haifei reported that Kangzhi Pharmaceutical (300086), which was suspended due to media queries, issued a clarification announcement yesterday, saying that there was no undisclosed related party transaction, and that it did not take fictitious transactions, advertising cash arbitrage and other means to increase sales and profits After resumption of trading yesterday, the company's share price once fell a lot, but it soon recovered from the bottom under the entry of funds for bottom hunting, closing down only 3.7% In view of the related party transactions, the company indicated that there was no undisclosed related party relationship and related party transactions After verification, Zhongrui consultant and Guangdong Kangzhi were the related parties of the company, and they had no relationship with the company after the equity transfer; Guangdong medical trade is still the related party of the company, and Guangzhou Zhongrui has been revoked its business license and closed for many years, resulting in the failure of industrial and commercial change procedures; Guangdong Tonghui has no relationship with the company In addition, Hainan Zhongrui had no relationship with the company after the equity transfer on September 29, 2007 Because Chen Haizhen was a supervisor of the company from January 10 to June 6, 2009, and also served as the legal representative of Hainan Zhongrui, Hainan Zhongrui became a related party of the company from January 10, 2009 to June 6, 2010, but there was no transaction between Hainan Zhongrui and the company in 2009 and 2010   In response to the query of "virtual increase in profits of Kangzhi pharmaceutical industry", the announcement said that in order to reduce transaction costs, simplify transaction procedures and make full use of Hainan's unique preferential policies, Kangzhi marketing and four suppliers such as Jieyang mayor Mao Pharmaceutical Co., Ltd and Guangdong Daxiang Pharmaceutical Co., Ltd adopted the "drug direct transfer business" transaction mode approved by the pharmaceutical regulatory department in the actual operation, namely, drug After purchasing drugs from drug production or wholesale enterprises, the drug logistics process of a drug handling enterprise is directly transferred to the next drug handling enterprise without being transferred by the enterprise itself The announcement details the transactions between Kangzhi pharmaceutical and the above seven companies in 2011 and 2012 Both parties of such transactions have signed contracts, issued invoices, collected or paid for goods, and obtained relevant transaction information such as customer's receipt voucher and logistics certificate All transactions are true According to the company, the gross profit of such exchanges accounts for only 0.95% and 2.22% of the company's overall gross profit.